Lazertinib: all 30 studies that test it

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCRecruitingNCT07586202Phase 2
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06667076Phase 2
• Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib TreatmentRecruitingNCT06106802Phase 2
• Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib MonotherapyNot yet recruitingNCT06020989Phase 2
• To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET DysregulationRecruitingNCT05541822Phase 2
• A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation TherapyRecruitingNCT05338619Phase 2
• A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailureActive, not recruitingNCT04988295Phase 3Results posted
• A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04487080Phase 3Results posted
• Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)CompletedNCT04248829Phase 3Results posted
• A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT04075396Phase 1/2Results posted
• Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung CancerActive, not recruitingNCT06268210Phase 2
• A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult ParticipantsCompletedNCT05896683Phase 1
• Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior LazertinibCompletedNCT05786430Phase 2
• A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult ParticipantsCompletedNCT05742594Phase 1
• Lazertinib 160mg in EGFR T790M NSCLCStatus unknownNCT05701384Phase 2
• Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKIActive, not recruitingNCT05601973Phase 2
• Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain MetastasesTerminatedNCT05477615Phase 2
• Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve PatientsActive, not recruitingNCT05463224Phase 2
• Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.Status unknownNCT05326425Phase 2
• Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor MutationsCompletedNCT05299125Phase 2
• Lazertinib for Patients With NSCLC Harboring Uncommon EGFR MutationsStatus unknownNCT05277701Phase 2
• Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.CompletedNCT05162274Phase 1
• A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)CompletedNCT05112952Phase 1
• A Study of Lazertinib (JNJ-73841937) in Healthy ParticipantsCompletedNCT05076877Phase 1
• A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT04965090Phase 2
• A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult ParticipantsCompletedNCT04410094Phase 1
• A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male ParticipantsCompletedNCT04410081Phase 1
• A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung CancerActive, not recruitingNCT04077463Phase 1
• Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448CompletedNCT03556436Phase 1
• Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLCCompletedNCT03046992Phase 1/2

← Lazertinib overview